Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today...

Related Keywords

James Chung ,Jamesn Kochenderfer ,Dominic Borie ,National Cancer Institute ,National Institutes Of Health ,National Institutes ,Chief Medical ,Kyverna ,